Clinical and causality assessment in herbal hepatotoxicity

Expert Opinion on Drug Safety

Volumn 12, Issue 3, 2013, Pages 339-366

  Teschke, Rolf ^a   Schwarzenboeck, Alexander ^a   Eickhoff, Axel ^a   Frenzel, Christian ^b   Wolff, Albrecht ^c   Schulze, Johannes ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Herb induced liver injury; Herbal hepatotoxicity; Herbal medicine; Herbs

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; HERBACEOUS AGENT; SOLUBILIZER; SOLVENT; URSODEOXYCHOLIC ACID;

DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG SURVEILLANCE PROGRAM; ERB INDUCED LIVER INJURY; HERB; HERB INDUCED LIVER INJURY; HUMAN; INTROSPECTION; LABORATORY TEST; LATENT PERIOD; LIVER HISTOLOGY; LIVER INJURY; LIVER TOXICITY; MEDLINE; REVIEW; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT INDICATION;

ANIMALS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84876586663     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.774371     Document Type: Review

References (101)

1. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76
2. Andrade RJ, Camargo R, Lucena MI, et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004;3:329-44 (Pubitemid 39023082)
3. Agarwal VK, McHutchison JG, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010;8:463-70
4. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59
5. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003;138:852-8 (Pubitemid 36960946)
6. Seeff KB. Herbal hepatotoxicity. Clin Liv Dis 2007;11:577-96
7. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009;29:373-82
8. Teschke R, Wolff A, Frenzel C, et al. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012;32:1543-56
9. Teschke R, Frenzel C, Glass X, et al. Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol 2013;75:630-6
10. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459-63 (Pubitemid 47631759)
11. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002;36:451-5 (Pubitemid 34810366)
12. Navarro VJ, Senior JR. Drug-related hepatotoxicity. NEJM 2006;354:73-739
13. De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80 (Pubitemid 38901470)
14. Chalasani N, Fontana RJ, Bonkovsky HL, et al. For the Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34
15. Blumenthal M, Lindstrom A, Ooyen C, et al. Herb supplement sales increase 4.5% in 2011. HerbalGram 2012;95:60-4
16. WHO. Guideline on good agricultural and collection practices (GACP) for medicinal plants. Geneva, WHO, 2003. Available from: http://whqlibdoc.who.int/ publications/2003/9241546271.pdf [Accessed 3 September 2012]
17. WHO. Technical Report Series, No. 937, 2006. Annex 3. Supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines. Available from: http://infocollections.org/medregpack/documents/ d0099/d0099.pdf [Accessed 3 September 2012]
18. WHO. Guidelines for assessing quality of herbal medicines with reference to contaminants and residues. 2007.Available from: http://apps.who.int/ medicinedocs/documents/s14878e/s14878e.pdf [Accessed 3 September 2012]
19. Teschke R, Lebot V. Proposal for a Kava Quality Standardization Code. Food Chem Toxicol 2011;49:2503-16
20. Lebot V. The quality of kava consumed in the South Pacific. HerbalGram 2006;71:34-7
21. Schmidt M. Quality criteria for kava. HerbalGram 2007;73:45-9
22. Teschke R, Qiu SX, Xuan TD, et al. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res 2011;25:1262-74
23. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany). Rejection of Drug Risks, Step II. As related to: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. June 14, 2002. Available from: http://www.spc.int/cis/documents/02-0714-BfArM-Kava-Removal.pdf [Accessed 3 September 2012]
24. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008;20:1182-93
25. Teschke R. Kava hepatotoxicity-a clinical review. Ann Hepatol 2010;9:251-65
26. Teschke R, Sarris J, Lebot V. Kava hepatotoxicity solution: a six-point plan for new kava standardization. Phytomedicine 2011;18:96-103
27. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010;30:1270-9
28. WHO (World Health Organization). Assessments of the risk of hepatotoxicity with kava products. WHO Document Production Services, Geneva, Switzerland; 2007
29. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628-38
30. EMA: assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, root). Issued May 8, 2007. Available from: http://www. ema.europa.eu/docs/en-GB/document-library/ Herbal-HMPC-assessment-report/2010/02/WC500074167.pdf [Accessed 3 September 2012]
31. Teschke R. Black cohosh and suspected hepatotoxicity-inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010;17:426-40
32. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver unspecific Naranjo scale precise enough to ascertain causality Pharmacoepidemiol Drug Saf 2011;20:567-82
33. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, et al. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011;11:249-59
34. Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011;61:282-91
35. Teschke R, Glass X, Schulze J, et al. Suspected Greater Celandine hepatotoxicity: liver specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol 2012;24:270-80
36. Teschke R, Frenzel C, Glass X, et al. Greater Celandine hepatotoxicity: a clinical review. Ann Hepatol 2012;11:838-48
37. Teschke R, Frenzel C, Schulze J, et al. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained Regul Toxicol Pharmacol 2012;63:1-9
38. Teschke R, Frenzel C, Wolff A, et al. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvements. Ann Hepatol 2012;11:500-12
39. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Ass 2010;304:2174-5
40. Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009;205:399-407
41. Health Canada. Black cohosh products and liver toxicity: update. Canadian Adverse Reaction Newsletter 2010;20:1-3.Available from: http://www. hc-sc.gc.ca/dhp-mps/medeff/bulletin/carnbcei-v20n1-eng.php#a1t1 [[Accessed 3 September 2012]
42. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998;339:847
43. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997;37:344-50 (Pubitemid 27184660)
44. Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995;333:803-4
45. Gertner E, Marshall PS, Filandrinos D, et al. Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs. Arthritis Rheum 1995;38:614-17
46. Kang-Yum E, Oransky SH. Chinese patent medicine as a potential source of mercury poisoning. Vet Hum Toxicol 1992;34:235-8
47. Teschke R, Sarris J, Lebot V. Contaminant hepatotoxins as culprits for kava hepatotoxicity-fact or fiction Phytother Res 2013; DOI: 10.1002/ptr.4729
48. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995;90:831-3
49. Perharic-Walton L, Murray V. Toxicity of traditional Chinese herbal remedies. Lancet 1992;340:674
50. Davies EG, Pollock I, Steel HM. Chinese herbs for eczema. Lancet 1990;336:117
51. Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995;36:146-7
52. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huang toxicity. Arch Intern Med 1996;156:899-903 (Pubitemid 26120595)
53. Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994;121:729-35
54. Nadir A, Agrawal S, King PD, et al. Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang. Am J Gastroentol 1996;91:1436-8
55. Itoh S, Marutani K, Nishijima T, et al. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hutang). Dig Dis Sci 1995;40:1845-8
56. Larrey D, Vial T, Pauwels A, et al. Hepatitis after Germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992;117:129-32
57. Laliberté L, Villeneuve JP. Hepatitis after the use of Germander, a herbal remedy. Can Med Assoc J 1996;154:1689-92 (Pubitemid 26178864)
58. Strahl S, Ehret V, Dahm HH, et al. Necrotising hepatitis after taking herbal remedies. Dtsch Med Wschr 1998;123:1410-14; Article in German (Pubitemid 28545594)
59. Benninger J, Schneider HT, Schuppan D, et al. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Gastroenterology 1999;117:1234-7 (Pubitemid 29512684)
60. Stickel F, Poschl G, Seitz HK, et al. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003;38:565-8 (Pubitemid 36609866)
61. Elinav E, Pinkser G, Safadi R, et al. Association between consumption of Herbalife-nutritional supplements and acute hepatotoxicity. J Hepatol 2007;47:514-20
62. Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife-products. J Hepatol 2007;47:521-6 (Pubitemid 47331751)
63. Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J 1981;282:186-7 (Pubitemid 11188566)
64. Beuers U, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet 1991;337:372-3
65. Yang L, Aronsohn A, Hart J, et al. Herbal hepatotoxicity from Chinese skullcap: a case report. World J Hepatol 2012;4(7):231-3
66. Danan G, Bénichou C; Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30 (Pubitemid 23333873)
67. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6 (Pubitemid 23333874)
68. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008;66:758-66
69. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008 Expert Opin Drug Metab Toxicol 2009;5:843-60
70. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80
71. Teschke R, Frenzel C, Wolff A, et al. Rare statin hepatotoxicity: convincing evidence based on breakthrough case study. J Hepatol 2012;57:699-700
72. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009;62:481-92
73. Dunbar K, Solga SF. Black cohosh, safety, and public awareness. Liver Int 2007;27:1017-18 (Pubitemid 47261958)
74. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009;16:72-84
75. Teschke R, Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. Ann Hepatol 2009;8:258-66
76. Garća-Cortés M, Borraz Y, Lucena MI, et al. Liver injury induced by "natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev Esp Enferm Dig 2008;100:688-95; Article in Spanish
77. Teschke R, Bahre R, Fuchs J, et al. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009;16:956-65
78. Andrade RJ, Lucena MI, Fernández MC, et al. Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21 (Pubitemid 41096639)
79. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-30 (Pubitemid 32016894)
80. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999;44:731-5 (Pubitemid 29195925)
81. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999;319:154
82. Rochon J, Protiva P, Seeff LB, et al. For the Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-83
83. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-35 (Pubitemid 350045603)
84. Davern TJ, Chalasani N, Fontana RJ, et al. For the Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011;141:1665-72
85. Hung SK, Hillier S, Ernst E. Case reports of adverse effects of herbal medicinal products (HMPs): a quality assessment. Phytomedicine 2011;18:335-43
86. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. 2001;33:308-10
87. WHO, World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database
88. 2000. Available from: http://who-umc. org/Graphics/24734.pdf [Accessed 3 September 2012]
89. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45 (Pubitemid 12149145)
90. Garća-Cortés M, Stephens C, Lucena MI, et al. on behalf of the Spanish Group for the Study of Drug-Induced Liver Disease. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55:683-91
91. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate Regul Toxicol Pharmacol 2011;59:1-7
92. Tajiri K, Shimizu Y. Practical guideline for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008;14:6774-85
93. Kramer MS. Assessing causality of adverse drug reactions: global introspection and its limitations. Drug Inf J 1986;20:433-7 (Pubitemid 17004492)
94. Teschke R, Frenzel C, Schulze J, et al. Suspected herbal hepatotoxicity: the pharmacovigilance dilemma with disputed and obsolete evaluation methods. Regul Toxicol Pharmacol 2012;64:343-4
95. Stammschulte T, Gundert-Remy U. Letter to the Editor. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained Regul Toxicol Pharmacol 2012;64:342
96. Teschke R, Eickhoff A, Wolff A, et al. Herbal hepatotoxicity and WHO global introspection. Ann Hepatol 2013;12:11-21
97. Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012;35:1091-7
98. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf 2008;31:469-84 (Pubitemid 351693681)
99. Weinstein DH, Twaddell WS, Raufman JP, et al. SlimQuick-associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity. World J Hepatol 2012;4:154-7
100. Inoue H, Yamazaki S, Shimizu M, et al. Liver injury induced by the Japanese herbal drug kamishoyosan. Gastroenterol Hepatol 2011;7:692-5
101. Nebraska judgement of 8. September 2006. Available from: http://ahpa.org/portals/0/pdfs/06-0908-Blackcohosh-NebraskaDistrictCt.pdf [Accessed 3 September 2012]